American Oriental Bioengineering Introduces Kangfuling Suppository

NEW YORK, Nov. 9, 2010 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), (the "Company" or "AOB"), a pharmaceutical company dedicated to improving healthcare through the development, manufacture and commercialization of a broad range of prescription and over-the-counter ("OTC") products, today announced the commercial launch of Jinji Kangfuling Suppository ("JKS"), a prescription herbal treatment for gynecological vaginitis due to microbial inflammation.

Mr. Tony Liu, Chairman and CEO of AOB, commented, "Our launch of JKS demonstrates our ability to drive innovation through research and development.  We are excited to leverage our knowledge of traditional Chinese medicine to provide an herbal solution for a common and chronic illness for women.  We are also excited to enter this large and growing market that is already estimated to gross approximately RMB 3.5 billion or about $500 million in sales annually. Furthermore, the addition of JKS, our first topical medication in this brand series, will enrich the product mix of our well-recognized Jinji Brand."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.  

Forward-Looking Statements

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995.  Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements.  The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2010, may cause actual results or events to differ materially from those described in the forward looking statements in this press release.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

SOURCE American Oriental Bioengineering, Inc.